LPCN
Lipocine Inc.
NASDAQ · USHealthcareBiotechnology
$2.15-3.59%
Price as of Jul 20, 2026
LPCN profitability
Lipocine Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -8.2%
- EBITDA margin
- -568.1%
- EBIT margin
- -605.9%
- Net margin
- -571.1%
- Free cash flow margin
- -501.9%
Returns
- Return on equity
- -50.1%
- Return on assets
- -45.1%
- Return on invested capital
- -53.1%
- Asset turnover
- 0.09x
Cash efficiency
- Cash from operations
- -$10.0M
- Cash per share
- $3.00
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.